

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Lentini Renee			2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) X Other (specify below) VP & PRIN ACCTG OFFICER		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/06/2023			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person _____		
C/O IMMUNOGEN, INC. 830 WINTER STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)			Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		
(Street)	(City)	(State)	(Zip)					
WALTHAM	MA		02451					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/06/2023		M		9,000	A	\$10.79	108,017	D	
Common Stock	11/06/2023		M		2,619	A	\$2.68	110,636	D	
Common Stock	11/06/2023		M		23,000	A	\$10.65	133,636	D	
Common Stock	11/06/2023		M		14,373	A	\$5.25	148,009	D	
Common Stock	11/06/2023		M		4,024	A	\$6.98	152,033	D	
Common Stock	11/06/2023		M		55,550	A	\$7.69	207,583	D	
Common Stock	11/06/2023		M		11,962	A	\$5.32	219,545	D	
Common Stock	11/06/2023		S		219,545	D	\$15.29 ⁽¹⁾	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivatives Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$10.79	11/06/2023		M			9,000	(2)	07/17/2024	Common Stock	9,000	\$0	0	D	
Stock Option (right to buy)	\$2.68	11/06/2023		M			2,619	(3)	09/30/2026	Common Stock	2,619	\$0	0	D	
Stock Option (right to buy)	\$10.65	11/06/2023		M			23,000	(4)	02/15/2028	Common Stock	23,000	\$0	0	D	
Stock Option (right to buy)	\$5.25	11/06/2023		M			14,373	(5)	01/31/2029	Common Stock	14,373	\$0	0	D	
Stock Option (right to buy)	\$6.98	11/06/2023		M			4,024	(6)	01/08/2031	Common Stock	4,024	\$0	12,625	D	
Stock Option (right to buy)	\$7.69	11/06/2023		M			55,550	(7)	02/05/2031	Common Stock	55,550	\$0	25,250	D	
Stock Option (right to buy)	\$5.32	11/06/2023		M			11,962	(8)	02/04/2032	Common Stock	11,962	\$0	53,831	D	

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.00 to \$15.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
2. This option was granted on 7/17/2014 and is fully vested as of the transaction date.
3. This option was granted on 9/30/2016 and is fully vested as of the transaction date.
4. This option was granted on 2/15/2018 and is fully vested as of the transaction date.
5. This option was granted on 1/31/2019 and is fully vested as of the transaction date.
6. This option was granted on 1/8/2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
7. This option was granted on 2/5/2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
8. This option was granted on 2/4/2022 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

/s/ Renee Lentini

11/08/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.